Core Viewpoint - Fortrea Holdings Inc. is facing potential legal claims due to allegations of misleading statements regarding its financial performance and business model, particularly related to its Pre-Spin Projects and cost savings from exiting Transitional Service Agreements (TSAs) [4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating claims against Fortrea and has set an August 1, 2025 deadline for investors to seek lead plaintiff status in a federal securities class action [2]. - Investors who suffered losses in Fortrea between July 3, 2023, and February 28, 2025, are encouraged to contact the firm to discuss their legal options [1]. Group 2: Financial Performance and Stock Price Impact - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting TSAs, leading to inflated EBITDA targets for 2025 [4]. - Following a downgrade by Jefferies on September 25, 2024, Fortrea's stock price fell by $2.73, or 12.29%, closing at $19.48 per share [5]. - A subsequent downgrade by Baird on December 6, 2024, after the cancellation of two conferences, resulted in a further stock price decline of $1.90, or 8.06%, closing at $21.67 per share [6]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a significant stock price drop of $3.47, or 25.05%, closing at $10.38 per share [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and IPO funding [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against Zenas, with a deadline of June 16, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Zenas materially overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to misleading public statements [4]. Group 2: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Any member of the class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5]. Group 3: Additional Information - Faruqi & Faruqi encourages anyone with information regarding Zenas' conduct, including whistleblowers and former employees, to contact the firm [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Red Cat To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Faruqi ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify misled investors by failing to disclose that customers were shifting ad spending to closed platforms, where the company's capabilities were limited [5]. - It is claimed that the development of technology for closed platforms was more expensive and time-consuming than disclosed, impacting the monetization of DoubleVerify's high-margin Activation Services [5]. - Competitors were reportedly better positioned to incorporate AI into their offerings, adversely affecting DoubleVerify's competitive stance and profitability [5]. - The company allegedly overbilled customers for ad impressions served to declared bots, and its risk disclosures were misleading, characterizing known adverse facts as mere possibilities [5]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a 36% drop in DoubleVerify's stock price following disappointing earnings and the suspension of services by a major customer [6]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [6]. Group 3: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is typical of class members, and any member can move to serve as lead plaintiff or remain an absent class member [7]. - Faruqi & Faruqi encourages anyone with information regarding DoubleVerify's conduct to come forward, including whistleblowers and former employees [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BigBear.ai To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in BigBear.ai between March 31, 2022 and March 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Far ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [4]. - Specific issues highlighted include the operational inefficiencies of the SmartDose device, which was expected to be a high-margin growth product but instead diluted profit margins [4]. - The allegations also mention the risk of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers, due to these margin pressures [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [5]. - Following this announcement, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on the same day [5]. Group 3: Legal Proceedings - Investors who purchased securities in West between February 16, 2023, and February 12, 2025, are encouraged to discuss their legal rights and options, with a deadline of July 7, 2025, to seek the role of lead plaintiff in the federal securities class action [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [6].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Red Cat To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ -- Far ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Canopy Growth Corporation due to allegations of misleading statements and undisclosed costs that negatively impacted the company's financial performance [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Canopy Growth and its executives violated federal securities laws by making false statements and failing to disclose significant costs related to the Claybourne product launch and Storz & Bickel vaporizer devices [4]. - Canopy reported a gross margin decrease of 400 basis points to 32% in Q3 2025, primarily due to costs associated with the Claybourne infused pre-roll launch and increased indirect costs related to vaporizer devices [5]. - The company experienced a wider-than-anticipated loss of C$1.11 per share in Q3 2025, compared to the C$0.48 per share loss estimated by analysts [5]. Group 2: Market Reaction - Following the announcement of the financial results, Canopy's share price fell by $0.76, or 27.34%, closing at $2.02 per share on February 7, 2025 [7]. Group 3: Legal Proceedings - Investors who purchased Canopy securities between May 30, 2024, and February 6, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and the June 3, 2025, deadline to seek lead plaintiff status in the class action [2][8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of misleading statements and failure to disclose critical information affecting investors [2][4]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify's customers are shifting ad spending from open exchanges to closed platforms, where the company's technological capabilities are limited [4]. - It is claimed that DoubleVerify's ability to monetize its high-margin Activation Services is constrained due to the high costs and time required for technology development for closed platforms [4]. - The complaint states that DoubleVerify's competitors are better positioned to incorporate AI into their offerings, negatively impacting DoubleVerify's competitive edge and profitability [4]. - Allegations include that DoubleVerify systematically overbilled customers for ad impressions served to declared bots, and that risk disclosures were materially false and misleading [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a significant stock price drop of 36% following disappointing earnings [5]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [5]. Group 3: Legal Proceedings - Investors who suffered losses in DoubleVerify are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options for participating in a federal securities class action [1][2]. - The deadline for seeking the role of lead plaintiff in the class action is set for July 21, 2025 [2].